HeartBeam, developer of a 3D-vector electrocardiogram (VECG) platform, has announced the appointment of Michael Jaff to its board of directors.
Jaff is chief medical officer and vice president of clinical affairs, technology and innovation of the Peripheral Interventions division at Boston Scientific. Previously, he was a professor of medicine at Harvard Medical School (Boston, USA) and he served as president of Newton-Wellesley Hospital (Newton, USA).
In a press release, HeartBeam described Jaff as a recognised expert in all aspects of vascular medicine. Jaff is the founder of VasCore, the Vascular Ultrasound Core Laboratory and has published over 300 peer-reviewed publications and 10 textbooks.
“I am passionate about innovation in health care and am excited to join the board at HeartBeam,” said Jaff. “Their technology has the potential to bring standard of care cardiac diagnostic technology directly to patients, improving outcomes and saving lives while reducing unnecessary expenditures. I look forward to contributing to these efforts.”
“Dr Jaff brings an extraordinary level of expertise to the HeartBeam board, with his extensive experience as a researcher, practicing clinician, hospital administrator, and industry executive,” said Rich Ferrari, Executive Chairman of HeartBeam. “His tremendous knowledge in clinical trial design and execution, as well as his experience supporting novel technologies in front of the Food and Drug Administration, will be valuable for the company.”
“We are thrilled to have Dr Jaff join our board,” added Branislav Vajdic, CEO and founder of HeartBeam. “He adds a unique and extremely valuable perspective that is crucial for HeartBeam as we progress toward our initial clearances and the commercial availability of our technology. The company will benefit from having the guidance of Dr Jaff, along with recent additions Ken Nelson and Mark Strome, at this exciting time.”
